Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Eagle Pharmaceuticals excels in 2022 with strong earnings growth

Eagle Pharmaceuticals' 2022 performance reflects strong earnings growth and operational efficiency, supported by key product sales and financial stability.
While facing challenges in managing expenses amidst investments, the company's strategic strengths lie in its product portfolio and financial resilience.
Opportunities for revenue growth and market expansion present avenues for Eagle Pharmaceuticals to further enhance its competitive position and drive future success.

Eagle Pharmaceuticals posts robust Q1 results, eyes strategic growth opportunities

Eagle Pharmaceuticals delivered a strong financial performance in Q1 2023, driven by key product sales and market share retention.
While facing challenges in expenses management, the company's solid cash position and growth strategies position it well for future opportunities.
Strategic initiatives like potential acquisitions and market expansion underscore Eagle Pharmaceuticals' commitment to sustained growth and innovation.

Eagle Pharmaceuticals beats Q2 estimates, eyes growth through strategic investments

Eagle Pharmaceuticals delivered a robust Q2 performance, exceeding expectations and demonstrating strong financial health. The company's strategic investments in R&D and commercial infrastructure position it well for future growth. Despite challenges and uncertainties, Eagle Pharmaceuticals remains optimistic about its continued growth trajectory and market prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The heavy selling pressure might have exhausted for Eagle Pharmaceuticals (EGRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround

WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the “Form 10-Q"), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934.

Eagle Delays Third Quarter 2023 Results and Conference Call

WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens.

Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023

NEW YORK--(BUSINESS WIRE)-- #healthcarecosts--TailorMed, a leading technology company offering the nation's largest network of patients, providers, pharmacies, life science companies, and other partners dedicated to improving healthcare affordability, today announced Eagle Pharmaceuticals, Inc. will be implementing TailorMed's Express Enroll solution. This partnership will introduce new efficiencies in seeking to secure financial assistance for patients prescribed Eagle's Pemfexy to manage and treat lung cancer.

TailorMed Partners with Eagle Pharmaceuticals to Streamline Patient Financial Assistance Enrollment

WOODCLIFF LAKE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,793,813 (“the ‘813 patent”) entitled “Pemetrexed Formulations.” Eagle has submitted the patent for listing in the U.S. Food and Drug Administration's Orange Book.1 The ‘813 patent is directed to pemetrexed formulations, including the FDA-approved commercial formulation of PEMFEXY®.

Eagle Pharmaceuticals Granted Patent for PEMFEXY®

-- J-code is effective January 1, 2024, and transitional pass-through status became effective October 1, 2023, facilitating patient access -- -- BARHEMSYS is the first and only antiemetic approved by the FDA for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV --

Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS

-- Study reports on an interim analysis of the pharmacokinetics and pharmacodynamics of remimazolam and a subsequent model-based optimization of the dosing regimen that is being studied in the trial -- -- Prize money to be donated to the University of Groningen Medical Center (“UMCG”) research fund, which supports the work of PhD students --

Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual Meeting

Acadia Healthcare

NeuroBo Pharmaceuticals Inc

Progyny

Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.

4 Undervalued Medical Stocks to Buy Amid High Market Volatility

WOODCLIFF LAKE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference 2023 as follows:

Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023

-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen's virulence factors to reduce damage and mitigate disease ---- The first-in-human study showed positive safety and efficacy when added to standard of care in patients with severe community-acquired bacterial pneumonia -- WOODCLIFF LAKE, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its abstract describing the global in-progress Phase 2 study of CAL02, a first-in-class, broad-spectrum, anti-virulence agent under development as an adjunct to antibiotic therapy for the treatment of severe community-acquired bacterial pneumonia (“SCABP”), has been selected for a poster presentation at the conference co-sponsored by the American Society for Microbiology (“ASM”) and the European Society for Clinical Microbiology and Infectious Diseases (“ESCMID”). This prestigious, multidisciplinary meeting is focused on the challenges, opportunities, and current requirements for antimicrobial drug development to address antimicrobial resistance. The conference is scheduled to take place September 19-22, 2023, in Boston, Massachusetts.

Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

-- Abstract compares relative effects on cognitive function following sedation with Byfavo (remimazolam) for injection versus midazolam -- Abstract compares relative effects on cognitive function following sedation with Byfavo (remimazolam) for injection versus midazolam

Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference

Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the dosing regimen for all fulvestrant patients and provide the opportunity for a more personalized treatment regimen in subpopulations, which represent over 50% of patients WOODCLIFF LAKE, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”).

Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women

WOODCLIFF LAKE, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the following healthcare conferences:

Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences

-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.701 ---- Reflects strength of Eagle's business and product pipeline; Company poised for sustained long-term growth -- WOODCLIFF LAKE, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today reiterated its previously issued guidance for the 2023 fiscal year. Full-year 2023 Adjusted non-GAAP EBITDA is expected to range from $78.0 to $84.0 million and Adjusted non-GAAP earnings per share is expected to range from $4.40 to $4.70.

Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - President and CEO Brian Cahill - CFO Conference Call Participants Tim Lugo - William Blair Operator Good morning, everyone. My name is Shelby and I will be your conference operator.

Eagle Pharmaceuticals, Inc. (EGRX) Q2 2023 Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.56 per share a year ago.

Eagle Pharmaceuticals (EGRX) Tops Q2 Earnings and Revenue Estimates

• Total revenue for Q2 2023 was $64.6 million • Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income1 was $1.18 per basic and diluted share • Q2 2023 net income was $5.2 million • Q2 2023 adjusted non-GAAP EBITDA1 was $20.7 million • Gross margin was 74% for the first half of 2023, up from 73% for the first half of 2022 • Adjusted non-GAAP gross margin1 was 83% for the first half of 2023, up from 74% for the first half of 2022 • Gross profit in its oncology business was $41.9 million in the second quarter of 2023 compared with $38.7 million in the prior year period, representing gross margin of 80% and 72%, respectively • Adjusted non-GAAP gross profit1 in its oncology business was $43.8 million in the second quarter of 2023 compared with $38.7 million in the prior year period, representing adjusted non-GAAP gross margin1 of 84% and 72%, respectively • An estimated 19,000 patients2 were dosed with Barhemsys® or Byfavo® during the second quarter of 2023; combined sales of Barhemsys and Byfavo were $1.2 million, representing approximately 30% sequential growth for the last two quarters • BENDEKA® and BELRAPZO® combined had approximately 84% share of the bendamustine U.S. market in the second quarter of 20233 • Company reiterates raised full-year guidance of adjusted non-GAAP EBITDA1 of $78.0-$84.0 million and adjusted non-GAAP earnings per share1 of $4.40-$4.70; resumed share repurchase program in July 2023 WOODCLIFF LAKE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and six months ended June 30, 2023.

Eagle Pharmaceuticals Reports Second Quarter 2023 Results

WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its second quarter 2023 financial results on Tuesday, August 8, 2023, before the market opens.

Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023

-- FY 2023 Adjusted non-GAAP earnings per share now expected to be $4.40 - $4.701 ---- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP R&D expense is reiterated at $41.0-$45.0 million1 ---- FY 2023 Adjusted non-GAAP SG&A expense is reiterated at $86.0-$90.0 million1 -- WOODCLIFF LAKE, N.J., July 31, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has raised its Adjusted non-GAAP earnings per share and Adjusted non-GAAP EBITDA guidance for the 2023 fiscal year. Full-year 2023 Adjusted non-GAAP earnings per share is now expected to range from $4.40 to $4.70, up from the previously disclosed estimated range of $4.20 to $4.53. Full-year 2023 Adjusted non-GAAP EBITDA is now expected to range from $78.0 to $84.0 million, up from the previously disclosed estimated range of $74.0 to $80.0 million. Full-year 2023 Adjusted non-GAAP research and development and Adjusted non-GAAP SG&A continue to be expected to range from $41.0-$45.0 million and $86.0-$90.0 million, respectively.

Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ Guidance

Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century 1

Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)

WOODCLIFF LAKE, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and reiterated its 2023 financial guidance.

Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance

Eagle Pharmaceutics Inc. EGRX said Wednesday it has won Food and Drug Administration Qualified Infectious Disease Product (QDIP) and Fast-Track Designation for CAL02, a treatment for severe community-acquired bacterial pneumonia (SCABP) as an add-on therapy to standard of care. The former designation will entitle the company to an additional eight to 10 years of regulatory exclusivity if the product is approved.

Eagle Pharmaceuticals gets FDA designations that will grant it extra exclusivity for bacterial pneumonia treatment

With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval

Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension

Abstracts to be presented cover preclinical data on RYANODEX® (dantrolene sodium) for injectable suspension in Acute Radiation Syndrome and Traumatic Brain Injury Abstracts to be presented cover preclinical data on RYANODEX® (dantrolene sodium) for injectable suspension in Acute Radiation Syndrome and Traumatic Brain Injury

News for Eagle Pharmaceuticals Stock (EGRX)